ストックスクリーナーアプリを入手
3.75
5.06%
-0.20
アフターアワーズ：
3.75
前日終値:
$3.95
開ける：
$3.94
24時間の取引高:
6,167
Relative Volume:
0.20
時価総額：
$177.77M
収益：
$27,600
当期純損益:
$-36.04M
株価収益率:
-4.7063
EPS:
-0.7968
ネットキャッシュフロー:
$-1.66M
1週間 パフォーマンス:
-6.95%
1か月 パフォーマンス:
+15.38%
6か月 パフォーマンス:
-21.05%
1年 パフォーマンス:
-40.48%
1日の値動き範囲:
$3.68
$3.94
1週間の範囲:
$3.60
$4.00
52週間の値動き範囲:
$2.76
$7.51
Nanobiotix Adr Stock (NBTX) Company Profile
NBTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
3.75 | 177.77M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-28 | 開始されました | Guggenheim | Buy |
| 2023-12-08 | 開始されました | Leerink Partners | Outperform |
| 2021-01-06 | 開始されました | Evercore ISI | Outperform |
Nanobiotix Adr (NBTX) 最新ニュース
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study - MSN
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Mexico Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Latin America Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Middle East & Africa Chitosan Market Size & Outlook, 2030 - Grand View Research
The United States Chitosan Market Size & Outlook, 2030 - Grand View Research
China Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Japan Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
symbol__ Stock Quote Price and Forecast - CNN International
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Nanobiotix Adr (NBTX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):